Purpose This study determined the prognostic value of volumetric parameters derived from pretreatment 18F-FDG and 18F-DOPA PET/CT of neuroblastoma and their correlation with clinical and histopathologic features. Patients and Methods A total of 25 children with neuroblastoma underwent pretreatment 18F-FDG and 18F-DOPA PET/CT within 4 weeks. The SUVmax of primary tumors on 18F-FDG and 18F-DOPA PET were recorded as SUVFDG and SUVDOPA, respectively. For volumetric parameters of primary tumors, 40% of SUVmax was used to generate volume of interest. If the 40% of SUVmax was below 2.5, an SUV threshold of 2.5 was used instead. Metabolic tumor volume (MTV), total lesion glycolysis (TLG), dopaminergic tumor volume (DTV), and total lesion 18F-DOPA activity (TLDA) were recorded as 18F-FDG and 18F-DOPA volumetric parameters. All indices were compared between groups distinguished by survival status and clinical features, including bone marrow involvement, lymph node metastasis, amplification of the MYCN oncogene, invasive features on anatomic images, and risk categories. The Kaplan-Meier method and log-rank test were used to compare the survival curves between groups. Results The median follow-up period was 28.2 months. Nonsurvivors (20%) tended to have lower SUVDOPA, DTV, and TLDA (P ≤ 0.05), and higher SUVFDG, MTV, and TLG (all P < 0.05). Lower 18F-DOPA uptake is associated with bone marrow and lymph node metastases (all P < 0.05). Higher 18F-FDG uptake is associated with MYCN amplification (all P < 0.05) and anatomic invasive features of tumors such as vascular encasement or adjacent organ invasion (TLG, P = 0.05). Only volumetric indices (DTV, TLDA, MTV, and TLG) significantly differed among risk groups (all P < 0.05). Conclusions Pretherapeutic 18F-DOPA and 18F-FDG PET provided complementary information, and both can be served for risk stratification. Volumetric indices of 18F-DOPA and 18F-FDG PET correlate more highly with risk grouping.
- risk stratification
- volumetric parameters
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging